• October 11, 2016

    Preparedness is also made of vigilance towards new infectious threats. Professor Bert Niesters from the University of Groningen, in the Netherlands, tells ASSET an example of spontaneous cooperation among 42 laboratories from more than 20 countries in Europe in facing an emerging, dangerous infection: enterovirus D68 respiratory epidemic in 2014-2015. That experience is now going on, taking the name of EUROTYPE.

  • September 21, 2016

    While the number of human cases of H7N9 bird flu is rising in China, and H5N1 is a persistent threat, different strategies of prevention are being considered. In a “one health” approach, vaccination of poultry is one of the possibilities, according to Ivan Hung, Clinical Associate Professor and Honorary Consultant in the Department of Medicine at the Queen Mary Hospital of the University of Hong Kong.

  • June 13, 2016

    One of the main source of distrust towards public health authorities is the suspect of hidden connections with the pharmaceutical industry, but, in case of a severe pandemic, an adequate supply of antivirals and vaccines is essential. ASSET asked Norman Begg, GSK Vice President, Head of Scientific Affairs and Public Health, Vaccines, what kind of agreements exist for Public Health Emergencies of International Concern (PHEIC) or of a pandemic, between big pharma and WHO. The answer for the two situations is not the same.

  • June 30, 2016

    Albert Osterhaus, director of the Research Center for Emerging Infections and Zoonoses (RIZ) in Hannover, Germany, and Chairman of the European Working group on Influenza (ESW), is one of the top virologist in the world, who has discovered more than 50 new viruses over the last decades. In this short video he explains why the word “pandemic” can be a cause of misunderstanding between health authorities and the public, as it happened in 2009, when the new emerging flu virus A(H1N1) turned out to be milder than expected in the beginning.

  • July 13, 2016

    Many clinical trials, even those on vaccines, are currently being made without considering the immunological differences that can exist between men and women. Katie Flanagan, senior lecturer of the Department of Immunology at Monash University, in Melbourne, Australia, explains how, and why this needs to be changed.

ASSET Analytics

Gender Platform

Ethic dataviz

Influenza pandemics are unpredictable but recurring events that can have severe consequences on human health and socio-economic life to global level. For this reason, the World Health Organization (WHO) has recommended all countries to prepare a pandemic influenza plan following its own guidelines.

One day, eight countries, fifty participants for each of them, open discussions and a series of questions. These are the ingredients of the citizen consultations organized by ASSET on September 24th, to voice people’s opinion on epidemic preparedness and response.

Vaccines have had broad medical impact, but existing vaccine technologies and production methods are limited in their ability to respond to certain pathogens. Other hurdles are due to difficulties in large scale production. MycoSynVac project proposes a new way for developing vaccines, by using of cutting-edge synthetic biology methodologies to engineer Mycoplasma pneumoniae as a universal chassis for vaccination.

Work Packages

Dialogue & Participation
Study & Analysis
Action Plan Definition
Citizen Consultation
Mobilization and Mutual Learning
Policy Watch


MMLAP and other EU Projects

Health system analysis to support capacity development in response to the threat of pandemic influenza in Asia
Making society an active participant in water adaptation to global change
Public Participation in Developing a Common Framework for Assessment and Management of Sustainable Innovation
Effective communication in outbreak management: development of an evidence-based tool for Europe
Developing the framework for an epidemic forecast infrastructure
European monitoring of excess mortality for public health action
Modelling the spread of pandemic influenza and strategies for its containment and mitigation
Cost-effectiveness assessment of european influenza human pandemic alert and response strategies
Bridging the gap between science, stakeholders and policy makers
Promotion of immunization for health professionals in Europe
Towards inclusive research programming for sustainable food innovations
Medical ecosystem – personalized event-based surveillance
Public Engagement with Research And Research Engagement with Society
Computing Veracity – the Fourth Challenge of Big Data
Transparent communication in Epidemics: Learning Lessons from experience, delivering effective Messages, providing Evidence